The Board of Unichem Laboratories at its meeting held on 20 March 2023 to approve the appointment of Priti Puri (DIN: 07755966) as an Additional Non-executive Independent Director of the Company w.e.f. 21 March 2023 for a period of three (3) years,subject to the approval of the shareholders.

Powered by Capital Market - Live News

The approved ANDA is a generic version of Ranexa of Gilead Sciences Inc.

Ranolazine extended-release tablets are indicated for the treatment of chronic angina (chest pain).

The product will be commercialized from Unichem's Goa plant.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.

The company reported a consolidated net loss of Rs 63.93 crore in Q3 FY23 as against net loss of Rs 14.10 crore in Q3 FY22. Net sales declined 2.8% YoY to Rs 302.50 crore in the quarter ended 31 December 2022.

The scrip fell 1.96% to currently trade at Rs 287 on the BSE.

Powered by Capital Market - Live News

Net Loss of Unichem Laboratories reported to Rs 63.93 crore in the quarter ended December 2022 as against net loss of Rs 14.10 crore during the previous quarter ended December 2021. Sales declined 2.83% to Rs 302.50 crore in the quarter ended December 2022 as against Rs 311.31 crore during the previous quarter ended December 2021.

Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 6 February 2023.

Powered by Capital Market - Live News